BACKGROUND: Increasing access to drugs for the treatment of multidrug-resistant (MDR) tuberculosis is crucial but could lead to increasing resistance to these same drugs. In 2000, the international Green Light Committee (GLC) initiative began to increase access while attempting to prevent acquired resistance. METHODS: To assess the GLC's impact, we followed adults with pulmonary MDR tuberculosis from the start to the end of treatment with monthly sputum cultures, drug susceptibility testing, and genotyping. We compared the frequency and predictors of acquired resistance to second-line drugs (SLDs) in 9 countries that volunteered to participate, 5 countries that met GLC criteria, and 4 countries that did not apply to the GLC. RESULTS: In total, 832 subjects were enrolled. Of those without baseline resistance to specific SLDs, 68 (8.9%) acquired extensively drug-resistant (XDR) tuberculosis, 79 (11.2%) acquired fluoroquinolone (FQ) resistance, and 56 (7.8%) acquired resistance to second-line injectable drugs (SLIs). The relative risk (95% confidence interval [CI]) of acquired resistance was lower at GLC-approved sites: 0.27 (.16-.47) for XDR tuberculosis, 0.28 (.17-.45) for FQ, and 0.15 (.06-.39) to 0.60 (.34-1.05) for 3 different SLIs. The risk increased as the number of potentially effective drugs decreased. Controlling for baseline drug resistance and differences between sites, the odds ratios (95% CIs) were 0.21 (.07-.62) for acquired XDR tuberculosis and 0.23 (.09-.59) for acquired FQ resistance. CONCLUSIONS: Treatment of MDR tuberculosis involves substantial risk of acquired resistance to SLDs, increasing as baseline drug resistance increases. The risk was significantly lower in programs documented by the GLC to meet specific standards. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Increasing access to drugs for the treatment of multidrug-resistant (MDR) tuberculosis is crucial but could lead to increasing resistance to these same drugs. In 2000, the international Green Light Committee (GLC) initiative began to increase access while attempting to prevent acquired resistance. METHODS: To assess the GLC's impact, we followed adults with pulmonary MDR tuberculosis from the start to the end of treatment with monthly sputum cultures, drug susceptibility testing, and genotyping. We compared the frequency and predictors of acquired resistance to second-line drugs (SLDs) in 9 countries that volunteered to participate, 5 countries that met GLC criteria, and 4 countries that did not apply to the GLC. RESULTS: In total, 832 subjects were enrolled. Of those without baseline resistance to specific SLDs, 68 (8.9%) acquired extensively drug-resistant (XDR) tuberculosis, 79 (11.2%) acquired fluoroquinolone (FQ) resistance, and 56 (7.8%) acquired resistance to second-line injectable drugs (SLIs). The relative risk (95% confidence interval [CI]) of acquired resistance was lower at GLC-approved sites: 0.27 (.16-.47) for XDR tuberculosis, 0.28 (.17-.45) for FQ, and 0.15 (.06-.39) to 0.60 (.34-1.05) for 3 different SLIs. The risk increased as the number of potentially effective drugs decreased. Controlling for baseline drug resistance and differences between sites, the odds ratios (95% CIs) were 0.21 (.07-.62) for acquired XDR tuberculosis and 0.23 (.09-.59) for acquired FQ resistance. CONCLUSIONS: Treatment of MDR tuberculosis involves substantial risk of acquired resistance to SLDs, increasing as baseline drug resistance increases. The risk was significantly lower in programs documented by the GLC to meet specific standards. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Green Light Committee; extensively drug-resistant tuberculosis; multidrug-resistant tuberculosis; tuberculosis
Authors: Rajesh Gupta; J Peter Cegielski; Marcos A Espinal; Myriam Henkens; Jim Y Kim; Catherina S B Lambregts-Van Weezenbeek; Jong-Wook Lee; Mario C Raviglione; Pedro G Suarez; Francis Varaine Journal: Trop Med Int Health Date: 2002-11 Impact factor: 2.622
Authors: M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: Tracy Dalton; Peter Cegielski; Somsak Akksilp; Luis Asencios; Janice Campos Caoili; Sang-Nae Cho; Vladislav V Erokhin; Julia Ershova; Ma Tarcela Gler; Boris Y Kazennyy; Hee Jin Kim; Kai Kliiman; Ekaterina Kurbatova; Charlotte Kvasnovsky; Vaira Leimane; Martie van der Walt; Laura E Via; Grigory V Volchenkov; Martin A Yagui; Hyungseok Kang; Rattanawadee Akksilp; Wanlaya Sitti; Wanpen Wattanaamornkiet; Sofia N Andreevskaya; Larisa N Chernousova; Olga V Demikhova; Elena E Larionova; Tatyana G Smirnova; Irina A Vasilieva; Alena V Vorobyeva; Clifton E Barry; Ying Cai; Isdore C Shamputa; Jaime Bayona; Carmen Contreras; Cesar Bonilla; Oswaldo Jave; Jeannette Brand; Joey Lancaster; Ronel Odendaal; Michael P Chen; Lois Diem; Beverly Metchock; Kathrine Tan; Allison Taylor; Melanie Wolfgang; Eunjin Cho; Seok Yong Eum; Hyun Kyung Kwak; Jiim Lee; Jongseok Lee; Seonyeong Min; Irina Degtyareva; Evgenia S Nemtsova; Tatiana Khorosheva; Elena V Kyryanova; Grace Egos; Ma Therese C Perez; Thelma Tupasi; Soo Hee Hwang; Chang-ki Kim; Su Young Kim; Hee Jeong Lee; Liga Kuksa; Inga Norvaisha; Girts Skenders; Ingrida Sture; Tiina Kummik; Tatiana Kuznetsova; Tatiana Somova; Klavdia Levina; Gustavo Pariona; Gloria Yale; Carmen Suarez; Eddy Valencia; Piret Viiklepp Journal: Lancet Date: 2012-08-30 Impact factor: 79.321
Authors: Scott K Heysell; Suporn Pholwat; Stellah G Mpagama; Saumu J Pazia; Happy Kumburu; Norah Ndusilo; Jean Gratz; Eric R Houpt; Gibson S Kibiki Journal: Antimicrob Agents Chemother Date: 2015-08-24 Impact factor: 5.191
Authors: John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler Journal: Am J Respir Crit Care Med Date: 2017-11-01 Impact factor: 21.405
Authors: Natasha Van't Boveneind-Vrubleuskaya; Tatiana Seuruk; Kai van Hateren; Tridia van der Laan; Jos G W Kosterink; Tjip S van der Werf; Dick van Soolingen; Susan van den Hof; Alena Skrahina; Jan-Willem C Alffenaar Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Jan-Willem C Alffenaar; Mathieu Bolhuis; Kai van Hateren; Marieke Sturkenboom; Onno Akkerman; Wiel de Lange; Ben Greijdanus; Tjip van der Werf; Daan Touw Journal: Antimicrob Agents Chemother Date: 2015-07-06 Impact factor: 5.191
Authors: Devyani Deshpande; Jotam G Pasipanodya; Stellah G Mpagama; Paula Bendet; Shashikant Srivastava; Thearith Koeuth; Pooi S Lee; Sujata M Bhavnani; Paul G Ambrose; Guy Thwaites; Scott K Heysell; Tawanda Gumbo Journal: Clin Infect Dis Date: 2018-11-28 Impact factor: 9.079
Authors: Aditya Sharma; Andrew Hill; Ekaterina Kurbatova; Martie van der Walt; Charlotte Kvasnovsky; Thelma E Tupasi; Janice C Caoili; Maria Tarcela Gler; Grigory V Volchenkov; Boris Y Kazennyy; Olga V Demikhova; Jaime Bayona; Carmen Contreras; Martin Yagui; Vaira Leimane; Sang Nae Cho; Hee Jin Kim; Kai Kliiman; Somsak Akksilp; Ruwen Jou; Julia Ershova; Tracy Dalton; Peter Cegielski Journal: Lancet Infect Dis Date: 2017-05-09 Impact factor: 25.071